Cargando…

Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma

BACKGROUND: High-grade serous ovarian carcinoma is highly heterogeneous, and although many studies have been conducted to identify high-grade serous ovarian carcinoma molecular subtypes that are sensitive to immunotherapy, no precise molecular subtype has been proposed to date. Immune cell infiltrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ping, Chen, Ruoxu, Zhang, Xudong, Fu, Ruiting, Tao, Lin, Jia, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759258/
https://www.ncbi.nlm.nih.gov/pubmed/35026984
http://dx.doi.org/10.1186/s12864-021-08265-y
_version_ 1784633073780916224
author Liu, Ping
Chen, Ruoxu
Zhang, Xudong
Fu, Ruiting
Tao, Lin
Jia, Wei
author_facet Liu, Ping
Chen, Ruoxu
Zhang, Xudong
Fu, Ruiting
Tao, Lin
Jia, Wei
author_sort Liu, Ping
collection PubMed
description BACKGROUND: High-grade serous ovarian carcinoma is highly heterogeneous, and although many studies have been conducted to identify high-grade serous ovarian carcinoma molecular subtypes that are sensitive to immunotherapy, no precise molecular subtype has been proposed to date. Immune cell infiltration and immune checkpoints are highly correlated with immunotherapy. Here, we investigated immune cell infiltration and immune checkpoint values for prognosis and precise immunotherapy for high-grade serous ovarian carcinoma based on molecular subtype classification. RESULTS: “High antigen-presenting cells infiltration molecular subtype of high-grade serous ovarian carcinoma” was identified in immune cell infiltration profiles. Each of the three immune cell infiltration clusters (A, B, and C) demonstrated distinct immune cell characterization, with immune cell infiltration cluster C exhibiting high antigen-presenting cell infiltration, improved prognosis, and higher sensitivity to immunotherapy. Programmed death-1/programmed death ligand 1 has a prognostic and predictive role that can help classify molecular subtypes. CONCLUSIONS: Our findings redefined a unique molecular subtype of high-grade serous ovarian carcinoma, suggesting that high-grade serous ovarian carcinoma patients with higher antigen-presenting cell infiltration and programmed death-1/programmed death ligand 1 expression can benefit from precise immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-021-08265-y.
format Online
Article
Text
id pubmed-8759258
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87592582022-01-18 Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma Liu, Ping Chen, Ruoxu Zhang, Xudong Fu, Ruiting Tao, Lin Jia, Wei BMC Genomics Research BACKGROUND: High-grade serous ovarian carcinoma is highly heterogeneous, and although many studies have been conducted to identify high-grade serous ovarian carcinoma molecular subtypes that are sensitive to immunotherapy, no precise molecular subtype has been proposed to date. Immune cell infiltration and immune checkpoints are highly correlated with immunotherapy. Here, we investigated immune cell infiltration and immune checkpoint values for prognosis and precise immunotherapy for high-grade serous ovarian carcinoma based on molecular subtype classification. RESULTS: “High antigen-presenting cells infiltration molecular subtype of high-grade serous ovarian carcinoma” was identified in immune cell infiltration profiles. Each of the three immune cell infiltration clusters (A, B, and C) demonstrated distinct immune cell characterization, with immune cell infiltration cluster C exhibiting high antigen-presenting cell infiltration, improved prognosis, and higher sensitivity to immunotherapy. Programmed death-1/programmed death ligand 1 has a prognostic and predictive role that can help classify molecular subtypes. CONCLUSIONS: Our findings redefined a unique molecular subtype of high-grade serous ovarian carcinoma, suggesting that high-grade serous ovarian carcinoma patients with higher antigen-presenting cell infiltration and programmed death-1/programmed death ligand 1 expression can benefit from precise immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-021-08265-y. BioMed Central 2022-01-13 /pmc/articles/PMC8759258/ /pubmed/35026984 http://dx.doi.org/10.1186/s12864-021-08265-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Ping
Chen, Ruoxu
Zhang, Xudong
Fu, Ruiting
Tao, Lin
Jia, Wei
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
title Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
title_full Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
title_fullStr Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
title_full_unstemmed Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
title_short Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
title_sort combined pd-1/pd-l1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759258/
https://www.ncbi.nlm.nih.gov/pubmed/35026984
http://dx.doi.org/10.1186/s12864-021-08265-y
work_keys_str_mv AT liuping combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma
AT chenruoxu combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma
AT zhangxudong combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma
AT furuiting combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma
AT taolin combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma
AT jiawei combinedpd1pdl1andtumorinfiltratingimmunecellsredefinedauniquemolecularsubtypeofhighgradeserousovariancarcinoma